Hepion Pharmaceuticals, Inc. announced additional efficacy data for rencofilstat, its lead drug candidate for the treatment of metabolic dysfunction-associated steatohepatitis, fibrotic diseases, HCC, and other chronic diseases.
[Hepion Pharmaceuticals, Inc.]